This recent readout follows successful data from another combination including Braftovi in mCRC.

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...

Pfizer Inc. PFE on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength ...

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its top and bottom lines. The stock is coming under some pressure on Tuesday ...

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Pfizer made one thing clear this week: It's officially back in the obesity race.